Massachusetts Launches THC Potency Audits for Retail Cannabis

The Massachusetts Cannabis Control Commission will begin auditing THC potency levels across the state's regulated cannabis market, targeting products that fall outside a 25% variance from their labeled claims.

Under the new program, regulators will conduct random testing of retail cannabis products to verify that actual THC content matches what consumers see on packaging. Products testing between 75% and 125% of their stated potency will pass. Anything outside that range could trigger enforcement action.

The move comes as state regulators nationwide grapple with accuracy in cannabis testing. Massachusetts joins several other states that have implemented similar oversight programs after industry complaints about inflated potency claims and inconsistent lab results.

Why the 25% Threshold

The commission's decision to allow a 25% variance acknowledges the biological variability inherent in cannabis products. Unlike pharmaceutical drugs, cannabis flower and concentrates can have natural fluctuations in cannabinoid content based on factors like growing conditions, harvest timing, and storage.

But the threshold also reflects concerns that some operators may be gaming the system. In states like California and Oregon, regulators have uncovered cases where cultivators "lab shop"—sending samples to multiple testing facilities until they get favorable results. Higher THC numbers can command premium prices, creating a financial incentive for inflated claims.

Massachusetts has over 400 licensed cannabis retailers operating across the state, with adult-use sales exceeding $1.8 billion in 2023. The market has matured rapidly since recreational sales launched in 2018, but testing standards have lagged behind the pace of growth.

Industry Response

The audit program has received mixed reactions from Massachusetts cannabis operators. Some larger multi-state operators have welcomed the oversight, arguing that standardized testing protects consumer trust and levels the playing field.

Smaller cultivators, however, worry about the cost implications. If products fail the audit, operators must either relabel or destroy inventory—both expensive options for businesses already operating on thin margins. The commission has not yet specified what penalties will apply to repeat offenders.

Testing laboratories themselves face increased scrutiny under the program. The CCC will compare audit results against the original lab reports that accompanied products to market. Consistent discrepancies could put a lab's license at risk.

What Happens Next

The commission plans to roll out audits gradually, starting with flower products before expanding to concentrates and edibles. Officials have not disclosed how many products will be tested monthly or which retailers will be targeted first.

The program follows similar initiatives in Michigan, which began potency audits in 2022, and Colorado, where regulators have conducted random testing since 2020. Both states reported finding significant discrepancies in roughly 15-20% of tested products.

Massachusetts regulators will publish aggregate audit data quarterly but will not identify specific brands or retailers unless enforcement action is taken. The first round of testing is expected to begin within the next 30 days.

Policy experts suggest the Massachusetts program could become a model for other East Coast markets. Several states, including New York and New Jersey, are developing their adult-use testing frameworks and watching how established markets handle quality control.

The commission will hold a public hearing in March to gather feedback on the audit program and potentially adjust the variance threshold based on initial results.

---

This article is based on original reporting by ganjapreneur.com.